Bayer AG Owns Roundup
Roundup is owned by Bayer AG, a German multinational pharmaceutical and life sciences company. Bayer acquired Monsanto, the original developer of the glyphosate-based herbicide, in a $63 billion all-cash deal completed in June 2018. Today, Roundup remains one of the most widely used herbicides globally, and its regulatory and legal challenges fall under Bayer's crop science division.
More from this site
Keep reading the latest coverage
The Acquisition and Its Aftermath
Bayer's purchase of Monsanto was one of the largest chemical-industry mergers in history. The deal gave Bayer control of the Roundup brand, the glyphosate molecule, and a broad portfolio of seeds and traits. In the years following the acquisition, Bayer absorbed tens of thousands of lawsuits alleging that glyphosate causes cancer, including several high-profile jury verdicts in the United States. The company maintains that glyphosate is safe when used as directed and has settled the majority of those claims through a combination of court rulings and settlements.
Regulatory and Legal Landscape
The ownership of Roundup has placed Bayer at the center of a global debate over glyphosate regulation. Agencies such as the U.S. Environmental Protection Agency, the European Chemicals Agency, and the World Health Organization's International Agency for Research on Cancer have issued conflicting assessments of glyphosate's carcinogenicity. These regulatory differences shape how Bayer can market, label, and sell Roundup in different countries, and they continue to influence the company's litigation strategy and product stewardship commitments.
Impact on Bayer's Business
Roundup remains a cornerstone of Bayer's Crop Science segment, generating substantial revenue from both professional and consumer channels. The product's market dominance in non-selective herbicides gives Bayer significant pricing power, but it also exposes the company to ongoing reputational and financial risk. Investors monitor Bayer's Roundup-related reserves, litigation costs, and any regulatory restrictions on glyphosate as key indicators of the division's long-term value.